Literature DB >> 23041814

Association between preoperative statin therapy and postoperative infectious complications in patients undergoing cardiac surgery: a systematic review and meta-analysis.

Imad M Tleyjeh1, Faisal A Alasmari, Aref A Bin Abdulhak, Muhammad Riaz, Musa A Garbati, Patricia J Erwin, Tarek Kashour, Mouaz H Al-Mallah, Larry M Baddour.   

Abstract

Infectious complications of cardiac surgery are often severe and life threatening. Statins having both immunomodulatory and anti-inflammatory effects were intuitively thought to influence the development of postsurgical infections. We sought to systematically examine whether any association exists between statin use and risk of infectious complications in patients undergoing cardiac surgery. We searched Ovid MEDLINE, Ovid EMBASE, Thomson Scientific Web of Science, and Elsevier Scopus from inception through February 2011 for comparative studies examining the association between statin use and risk of postoperative infections in patients undergoing cardiac surgery. We contacted a study's author for missing information. We conducted a random-effects meta-analysis of individual studies' odds ratios (adjusted for potential confounders). We identified 6 cohort studies for inclusion, 3 of which were conducted in Canada and 3 of which were conducted in the United States. Four were single-center studies, and 2 were population based. Exposure ascertainment was based on a review of admission medication list or prescription databases. Infectious outcomes were heterogeneous and included surgical site infections within 30 days, serious infections (sepsis), or any other postoperative infection. Statin use in the preoperative period was associated with a trend toward reduction in the incidence of postoperative infections in patients who underwent cardiac surgery (odds ratio, 0.81 [95% confidence interval, 0.64-1.01]; [Formula: see text]; [Formula: see text]). Heterogeneity was explained by country effect. Studies performed in Canada showed weaker associations than studies performed in the United States. This difference could not be attributed to study quality alone. We did not find good evidence to support an association between statin use and postoperative infectious complications. However, the trend toward statistical significance for this association indicates that further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041814     DOI: 10.1086/668019

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  6 in total

1.  The association between donor and recipient statin use and infections after allogeneic hematopoietic cell transplantation.

Authors:  S Seo; M Boeckh; B E Storer; M M Schubert; M Rotta; B M Sandmaier; M Mielcarek
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

Review 2.  Preventing deep wound infection after coronary artery bypass grafting: a review.

Authors:  Charles S Bryan; William M Yarbrough
Journal:  Tex Heart Inst J       Date:  2013

3.  The reduction of post-cardiac surgery infections by statins: solid evidence?

Authors:  S C A M Bekkers
Journal:  Neth Heart J       Date:  2014-11       Impact factor: 2.380

4.  Effect of lipid-lowering medications in patients with coronary artery bypass grafting surgery outcomes.

Authors:  Chunxia Shi; Zugui Zhang; Jordan Goldhammer; David Li; Bob Kiaii; Victor Rudriguez; Douglas Boyd; David Lubarsky; Richard Applegate; Hong Liu
Journal:  BMC Anesthesiol       Date:  2022-04-26       Impact factor: 2.376

Review 5.  Does short preoperative statin therapy prevent infectious complications in adults undergoing cardiac or non-cardiac surgery? A meta-analysis of 5 randomized placebo-controlled trials.

Authors:  Hua Li; Yuan-Long Lin; Shu-Ling Diao; Bao-Xin Ma; Xian-Liang Liu
Journal:  Saudi Med J       Date:  2016-05       Impact factor: 1.484

6.  Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice.

Authors:  Elias A Rahal; Wissam N Constantin; Nabil Zeidan; Alexander M Abdelnoor
Journal:  Front Microbiol       Date:  2015-12-22       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.